<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862095</url>
  </required_header>
  <id_info>
    <org_study_id>208075</org_study_id>
    <nct_id>NCT00862095</nct_id>
  </id_info>
  <brief_title>Medical Therapies for Chronic Post-Traumatic Headaches</brief_title>
  <official_title>A Randomized Controlled Trial of Medical Therapies for Chronic Post-Traumatic Headaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Madigan Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Madigan Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if propranolol, amitriptyline, or topiramate decreases headache frequency in&#xD;
      patients with chronic post-traumatic headaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 240 patients meeting International Classification of Headache Disorders (ICHD)&#xD;
      diagnostic criteria for chronic post-traumatic headaches will be enrolled. Subjects will be&#xD;
      recruited from the Neurology Clinic at Madigan Army Medical Center. Study participants will&#xD;
      be U.S. Army soldiers who sustained a mild traumatic head injury while deployed to a combat&#xD;
      theater resulting in chronic post-traumatic headaches. Subjects will be randomized to&#xD;
      placebo, propranolol (target dose 80 mg a day), amitriptyline (target dose 50 mg a day), or&#xD;
      topiramate (target dose 100 mg a day) for 3 months.&#xD;
&#xD;
      The primary outcome measure will be the mean number of headache days per month on the third&#xD;
      month of treatment. Secondary outcome measures will include the proportion of subjects with&#xD;
      at least a 25% reduction in headache frequency, headache severity (0-10 scale), headache&#xD;
      duration (hours), headache-related disability (measured by the Headache Impact Test and&#xD;
      Migraine Disability Assessment Scale), PTSD symptom checklist score, and medication side&#xD;
      effects and tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inadequate enrollment, insufficient funds to continue enrollment&#xD;
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache days per month on the third month of treatment</measure>
    <time_frame>Monthly for 4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol (target dose 80 mg a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate (target dose 100 mg a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amitriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amitriptyline (target dose 50 mg a day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Every month for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>target does 80 mg per day for 3 months</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amitriptyline</intervention_name>
    <description>Target does of 50 mg per day for 3 months</description>
    <arm_group_label>Amitriptyline</arm_group_label>
    <other_name>Elavil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Target dose 100 mg a day for 3 months</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patient meets ICHD criteria for chronic post-traumatic headaches (see below).&#xD;
&#xD;
          2. Patient is 18-50 years old.&#xD;
&#xD;
          3. Patient has experienced 6 or more days of headache per month for each of the last 2&#xD;
             months.&#xD;
&#xD;
          4. Patient has full capacity to provide informed consent.&#xD;
&#xD;
          5. Patient will be available for all study-related visits over the next 4 months.&#xD;
&#xD;
          6. Patient must be eligible to receive care at Madigan Army Medical Center&#xD;
&#xD;
        International Classification of Headache Disorders (version 2) diagnostic criteria for&#xD;
        chronic post-traumatic headaches attributed to mild head injury:&#xD;
&#xD;
          1. Headaches beginning within 1 week of mild traumatic head injury.&#xD;
&#xD;
          2. Headaches persisting &gt; 3 months after head trauma.&#xD;
&#xD;
          3. Head trauma with all of the following:&#xD;
&#xD;
               -  no loss of consciousness or loss of consciousness &lt; 30 minutes&#xD;
&#xD;
               -  Glasgow Coma Score (GCS) 13-15&#xD;
&#xD;
               -  symptoms or signs diagnostic of concussion&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patient has another headache disorder not attributable to head trauma which accounts&#xD;
             for at least half of the patient's headache episodes.&#xD;
&#xD;
          2. Patient is currently taking propranolol, amitriptyline, or topiramate for any reason.&#xD;
&#xD;
          3. Patient previously tried propranolol, amitriptyline, or topiramate for headache&#xD;
             treatment.&#xD;
&#xD;
          4. Patient started a new treatment for headache prevention within the last 6 weeks.&#xD;
             Prophylactic treatments initiated prior to 6 weeks ago are allowed as long as the dose&#xD;
             or regimen is stable. Medications for aborting acute headaches are also allowed.&#xD;
&#xD;
          5. Patient previously tried more than two medications for headache prevention.&#xD;
&#xD;
          6. Patient is using narcotic analgesics on average more than 10 days a month.&#xD;
&#xD;
          7. Patient has a medical condition or is taking a medication that is considered a&#xD;
             contraindication for propranolol, topiramate, or amitriptyline. Medical conditions&#xD;
             include liver disease, renal impairment, cardiac dysrhythmias, untreated thyroid&#xD;
             disease, orthostatic hypotension, asthma requiring treatment with inhalers, glaucoma,&#xD;
             kidney stones, insulin-requiring diabetes, or pregnancy.&#xD;
&#xD;
          8. Patient has known hepatic, renal, or cardiac disorders.&#xD;
&#xD;
          9. Patient drinks on average more than two servings of alcohol (2 oz hard liquor, 5 oz&#xD;
             wine, 12 oz beer) per day or more than 3 servings at one time on a weekly basis.&#xD;
&#xD;
         10. Patient has abnormalities on baseline EKG.&#xD;
&#xD;
         11. Patient has major depression defined as a score &gt;15 on the Patient Health&#xD;
             Questionnaire-9.&#xD;
&#xD;
         12. Patient is pregnant, planning to become pregnant in the next year, or is a female of&#xD;
             reproductive potential who is not using a reliable form of birth control.&#xD;
&#xD;
         13. Patient has cognitive impairment defined as mini-mental status exam score &lt;27.&#xD;
&#xD;
         14. SBP &lt; 90, HR &lt; 50, or HR &gt; 100.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Erickson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madigan Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Madigan Army Medical Center</investigator_affiliation>
    <investigator_full_name>Jay C. Erickson</investigator_full_name>
    <investigator_title>Chief, Neurology Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

